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INTRODUCTION
•

•

Genetically Modified Organisms: any organism,
plant or animal which genetic material has
been modified not by natural recombination or
reproduction.
Living Modified Organisms: any organism, plant
or animal which genetic material has been
modified not by natural recombination or
reproduction, which is capable of replication.

INTRODUCTION
 Genetically

Modified (GM) products have increased on
the market as foods and food additives, beverages,
fuels and pharmaceutical products since the 1990’s
but there are concerns about potential side effects on
human health and the environment.
 From 1.7 million hectares of GM crops cultivated in
1996, this multi-billion-dollar global industry has
increased to 160 million hectares in 2011.

AT THE INTERNATIONAL LEVEL
 1992

Rio Summit: Agenda 21 (chapter 16)
 The 1992 Convention on Biodiversity (CBD) includes
international rules on access to genetic resources and
transfer of biotechnology techniques but no detailed
regulation on Genetically Modified Organisms (GMOs).
 The 2000 Cartagena Protocol on the safety of
transboundary movements of Living Modified Organisms
(LMOs), (Cartagena Protocol).
 The 2010 Nagoya-Kuala Lumpur Supplementary Protocol
on liability and redress for damages resulting from
transboundary movements of LMOs (the Nagoya
Supplementary Protocol).

KEY ISSUES TO BE ADDRESSED








The scope of the GMOs to be regulated
Identification and traceability issues
The relationship of the Cartagena Protocol with other
prior international agreements
Liability and redress issues
Harmonisation of biosafety regulation issues
Other issues (socio-economic considerations, risk
assessment and risk management, financial
guarantees, compliance…)

SCOPE OF THE GMOS COVERED








Only LMOs (but not GMOs) are covered by the
Cartagena Protocol and the Nagoya Supplementary
Protocol.
LMOs to be released into the environment (GM
seeds).
LMOs destined for contained use (GM viruses or
bacteria).
LMOs intended for direct use as food, feed or to be
processed (live GM salmon, GM grains intended for
feed) but there is no compliance mechanism as to the
final use of this category. GM food aid?

GMOS WHICH ARE NOT COVERED
 LMOs

to be used as raw material for the
production of pharmaceuticals.
 GM agricultural products with added health value
(nutraceuticals such as rice with enriched
vitamins) or GM products modified as edible
vaccines.
 GM additives and flavourings (GM strawberry).
 Products derived from LMOs to be used directly as
food and feed (oil, flour, tomato sauce, chicken
eggs from chicken fed with GM feed) which cannot
replicate themselves or transfer genetic material.

SCOPE OF THE ADVANCE INFORMED AGREEMENT
PROCEDURE



Not subjected to the AIA procedure:
Pharmaceuticals to be used by human beings which
are subjected to other agreements or relevant
international organisations are not subjected to the
AIA procedure however these instruments may deal
with human health concerns but do not address
directly the environmental and biodiversity impacts of
LMOs.

SCOPE OF THE ADVANCED INFORMATION AGREEMENT
PROCEDURE








Not subjected to the AIA procedure:
LMOs in contained use.
LMOs in transit (only placed under customs
procedures applicable in different States).
LMOs to be used as food and feed or food to be
processed.
Simplified procedures for LMOs considered as less
dangerous (Articles 11 and 13 of the Cartagena
Protocol).

MAIN ISSUES ABOUT LABELLING AND
TRACEABILITY:






Whether the labelling of GM products must be
mandatory or voluntary? No international labelling
obligation.
Which products should be labelled and the contents
of the labels?
Whether traces of GM content in the final product
must be labelled and at which thresholds? No
international threshold on the labelling of GM
products.

IDENTIFICATION AND TRACEABILITY ISSUES

Labelling obligation in the protocol only for
LMOs intended for direct use as food and feed
or to be processed (Annexure II of the
Cartagena Protocol).
 No official inspection mechanism for this
labelling obligation.
 Grain shippers have been using the “may
contain LMOs” designation on commercial
invoices.


IDENTIFICATION AND TRACEABILITY ISSUES







No international labelling obligation amounts to:
Different standards in different countries.
Consequences on the organic products’ industry.
No segregation and risks of mixing GM and non-GM
products during transboundary movements.
Lack of traceability of GM products in case of health
hazards or unintentional release into the environment.

RELATIONSHIP OF THE BIOSAFETY PROTOCOL WITH
OTHER PRIOR INTERNATIONAL AGREEMENTS
 The WTO Agreement on the application of Sanitary and
Phytosanitary Measures (the SPS Agreement).
 The WTO Agreement on Technical Barriers to Trade
(TBT Agreement).
 The General Agreement on Tariff and Trade (GATT)
1994
 The WTO Reference bodies (Codex Alimentarius, World
Health Organisation (WHO), World organisation for
Animal Health (OIE)).
 The International Plant Protection Convention (IPPC)

RELATIONSHIP OF THE BIOSAFETY PROTOCOL WITH
OTHER PRIOR INTERNATIONAL AGREEMENTS










Existence of a saving Clause in the Cartagena Protocol stating
that it is not subordinate or superior to other prior international
instruments.
The Cartagena Protocol applies only to LMOs whereas the trade
agreements apply to all categories of GMOs.
But the Cartagena Protocol fully applies to a transboundary
movement of LMOs for non-commercial purposes.
The Cartagena Protocol rests on the Precautionary principle
whereas the trade agreements apply the principle of
substantial equivalence.
Which standards will apply in case of international trade of
GMOs and which dispute settlement mechanism will apply?

LIABILITY AND REDRESS ISSUES




The Nagoya-Kuala Lumpur Supplementary Protocol
2010 sets up mainly administrative and civil liability
rules and procedures to be implemented by States
Parties.
The national competent authority of the country
affected by the damage needs to investigate the
matter, evaluate the damage and determine which
response measures need to be taken by the operator.

LIABILITY AND REDRESS ISSUES









Standard of civil liability (fault-based or strict liability)
for damages resulting from transboundary movements
of LMOs.
Causal link (the burden of proof will be different
depending on whether a fault-based or strict liability is
applicable).
Damages (adverse effects on the sustainable use of
biological diversity taking into account human health)
Exemption to liability (acts of war and civil unrest)
Which dispute settlement procedures will apply?

HARMONISATION OF BIOSAFETY REGULATION
ISSUES
Increase of national biosafety frameworks
(NBFs) since the adoption of the Cartagena
Protocol (in 2012, 118 States have NBFs).
 Influence of weaker or stronger regional
biosafety mechanisms.
 Influence of the biotech industry for weaker
mechanisms.
 Bilateral or multilateral agreements.


OTHER ISSUES








Socio-economic considerations (SA communication on
GM crops’ impact on small-scale farmers, Indian
farmers and the negative effects of using corporate GM
seeds instead of farm-saved seeds?)
Risk assessment and risk management (which
methods, sound science?)
Compliance (reporting, Biosafety Clearing House
(BCH..)
Financial guarantees in relation to transboundary
movements of LMOs.

CONCLUSION






The Cartagena Protocol provides for a baseline of legal
control on the import and export of GMOs that needs
to be translated into national regimes.
Additional categories of GMOs need to be regulated
since the Cartagena Protocol was drafted targetting
mainly GM agricultural products.
Need for a better control of illegal movement of GMOs
considered
as
hazardous
(pathogenic
GM
microorganisms) for public health or security
(bioterrorism).

CONCLUSION






Need for harmonisation of standards : different standards
applicable for different countries resulting in a less efficient
biosafety system.
Harmonisation of identification and traceability standards, risk
assessment and risk management standards and
communication of information on biotechnological risks.
Harmonisation with inter-State cooperation (at best by
competent international bodies) and not by influential private
actors with vested interests.

CONCLUSION







Need for an international liability and redress regime.
Procedures to bring redress depend too much on the area in
which the damage occurred and domestic laws on liability .
Damages caused to the neighbouring areas and their biological
diversity may be irreversible and there is no redress for damages
in areas beyond national jurisdiction.
20 years after Rio, existing biosafety instruments represent
milestones paving the way ahead. These existing biosafety
instruments need to be deepened and implemented at the
national level for more efficiency rather than elaborating more
instruments.

 Thank

you for your attention.

